Adverse effects: vaginal dryness · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in adverse effects: vaginal dryness compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Chemotherapy vs Placebo
Outcome not reported · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
The review found no eligible studies for this question.
1 finding from 1 review
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
1 finding from 1 review
Overall survival · people with metastatic CRC
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review